Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(J Pharm Pharm Sci)
739 results
  • Predicting High-Impact Pharmacological Targets by Integrating Transcriptome and Text-Mining Features. [Journal Article]
  • JPJ Pharm Pharm Sci 2016 Oct - Dec; 19(4):475-495
  • Mayburd A, Baranova A
  • CONCLUSIONS: A significant cost reduction may be achieved by a priori impact assessment of targets and ligands before their development or repurposing. Expanding a suite of combinational treatments could also decrease the costs, while achieving a higher impact per developed ligand. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.
  • Evaluation and Optimization of Blood Micro-Sampling Methods: Serial Sampling in a Cross-Over Design from an Individual Mouse. [Journal Article]
  • JPJ Pharm Pharm Sci 2016 Oct - Dec; 19(4):496-510
  • Patel NJ, Wickremsinhe E, … Perkins E
  • CONCLUSIONS:   Of the methods that allowed serial sampling, the saphenous method when executed as described in this report, was most practical, reproducible and provided for assessment of inter-animal variability.  It enabled the collection of complete exposure profiles from a single mouse and the conduct of an intravenous/oral cross-over study design.  This methodology can be used routinely, it promotes the 3Rs principles by achieving reductions in the number of animals used, decreased restraints and animal stress, and improved the quality of data obtained in mouse PK studies. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.
  • Ceftazidime/Avibactam: Who Says You Can't Teach an Old Drug New Tricks? [Journal Article]
  • JPJ Pharm Pharm Sci 2016 Oct - Dec; 19(4):448-464
  • Barber KE, Ortwine JK, Akins RL
  • CONCLUSIONS: By adding avibactam to ceftazidime, clinicians' antimicrobial armamentarium is expanded, potentially increasing the ability to combat multi-drug resistant gram-negative pathogens, particularly ESBL and carbapenemase-producing organisms, as well as Pseudomonas aeruginosa. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.
New Search Next